These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35111667)

  • 1. Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review.
    Zhu J; Tao J; Dai Z; Tan Y; Jiang L; Wang Q; Lang J
    Front Oncol; 2021; 11():771546. PubMed ID: 35111667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
    Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
    Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis.
    Ajani JA; Leung L; Singh P; Kurt M; Kim I; Pourrahmat MM; Kanters S
    Eur J Cancer; 2022 Jul; 170():119-130. PubMed ID: 35605522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review.
    Zhu J; Yang Y; Tao J; Wang SL; Chen B; Dai JR; Hu C; Qi SN; Li YX
    Leukemia; 2020 Oct; 34(10):2576-2591. PubMed ID: 32651542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma.
    Liu H; Wang Y; Qi C; Xie T; Peng Z; Li J; Shen L; Zhang X
    Front Oncol; 2022; 12():835389. PubMed ID: 35463354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review.
    Li Y; Liu H; Sun C; Yin X; Tong J; Zhang X; Wang X; Yuan X; Zhang Z; Lu G; Gu Y; Li Y; Huang T; Qiao Z; Chen Y
    Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):405-416. PubMed ID: 33964352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence for association of neoadjuvant chemotherapy or chemoradiotherapy with efficacy and safety in patients with resectable esophageal carcinoma (NewEC study).
    Zhou HY; Zheng SP; Li AL; Gao QL; Ou QY; Chen YJ; Wu ST; Lin DG; Liu SB; Huang LY; Li FS; Zhu HY; Qiao GB; Lanuti M; Yao HR; Yu YF
    EClinicalMedicine; 2020 Jul; 24():100422. PubMed ID: 32637899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Yang Y; Wang J; Wang W; Zhang T; Zhao J; Wang Y; Li Y; Wang L; Bi N
    Front Oncol; 2022; 12():810580. PubMed ID: 35155246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma.
    Blank O; von Tresckow B; Monsef I; Specht L; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD007110. PubMed ID: 28447341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis.
    Bao Y; Ma Z; Yuan M; Wang Y; Men Y; Hui Z
    Thorac Cancer; 2022 Sep; 13(17):2515-2523. PubMed ID: 35891585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
    Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
    Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2- metastatic breast cancer.
    Forsythe A; Chandiwana D; Barth J; Thabane M; Baeck J; Tremblay G
    Breast Cancer (Dove Med Press); 2018; 10():69-78. PubMed ID: 29765247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
    Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
    Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
    Bonnetain F; Bosset JF; Gerard JP; Calais G; Conroy T; Mineur L; Bouché O; Maingon P; Chapet O; Radosevic-Jelic L; Methy N; Collette L
    Eur J Cancer; 2012 Aug; 48(12):1781-90. PubMed ID: 22507892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades.
    Nishikawa G; Banik P; Thawani R; Kardosh A; Wood SG; Nabavizadeh N; Chen EY
    J Gastrointest Oncol; 2022 Jun; 13(3):1454-1466. PubMed ID: 35837173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinoma.
    Yang YX; Zheng YZ; Gao TT; Liu SL; Xi M; Liu MZ; Wang JY; Qi SN; Yang Y; Zhao L
    Cancer Med; 2022 Oct; 11(20):3751-3760. PubMed ID: 35434962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
    Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
    Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.